Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
grade C 17.62 -2.60% -0.47
NCNA closed down 2.6 percent on Monday, December 10, 2018, on 1.15 times normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NCNA trend table...

Date Alert Name Type % Chg
Dec 10 20 DMA Resistance Bearish 0.00%
Dec 10 50 DMA Resistance Bearish 0.00%
Dec 10 Bollinger Band Squeeze Range Contraction 0.00%
Dec 7 50 DMA Resistance Bearish -2.60%
Dec 7 Fell Below 20 DMA Bearish -2.60%
Dec 7 Pocket Pivot Bullish Swing Setup -2.60%
Dec 7 Bollinger Band Squeeze Range Contraction -2.60%
Dec 7 BB Squeeze Started Range Contraction -2.60%
Dec 7 BB Squeeze + Upper Band Touch Range Contraction -2.60%
Dec 7 Upper Bollinger Band Touch Strength -2.60%

Older signals for NCNA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Is NCNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.0
52 Week Low 9.32
Average Volume 61,262
200-Day Moving Average 22.0724
50-Day Moving Average 18.5338
20-Day Moving Average 18.148
10-Day Moving Average 18.139
Average True Range 1.6966
ADX 8.82
+DI 16.5144
-DI 16.597
Chandelier Exit (Long, 3 ATRs ) 14.9902
Chandelier Exit (Short, 3 ATRs ) 20.6398
Upper Bollinger Band 19.6082
Lower Bollinger Band 16.6878
Percent B (%b) 0.32
BandWidth 16.092131
MACD Line -0.1453
MACD Signal Line -0.164
MACD Histogram 0.0187
Fundamentals Value
Market Cap 560.51 Million
Num Shares 31.8 Million
EPS -0.40
Price-to-Earnings (P/E) Ratio -44.05
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.39
Resistance 3 (R3) 19.56 19.15 19.10
Resistance 2 (R2) 19.15 18.70 19.06 19.00
Resistance 1 (R1) 18.38 18.42 18.18 18.21 18.90
Pivot Point 17.97 17.97 17.86 17.88 17.97
Support 1 (S1) 17.20 17.52 17.00 17.03 16.34
Support 2 (S2) 16.79 17.24 16.70 16.24
Support 3 (S3) 16.02 16.79 16.15
Support 4 (S4) 15.85